FOLD №49 — REFINED

Semax His-3 → 1-Methyl-L-Histidine: Tautomer Locking for MC4R Affinity

Mechanism of Action

Semax (MEHFPGP) is a synthetic heptapeptide derived from the ACTH(4-7) core, extended with a Pro-Gly-Pro tail for metabolic stabilization. Its pharmacophore lineage traces to the conserved His-Phe-Arg-Trp (HFRW) tetrapeptide motif present in ACTH and α-MSH, which is the minimal sequence recognized by melanocortin receptors (MC1R–MC5R). In this pharmacophore, the histidine imidazole is understood to donate an H-bond to the conserved acidic cluster (Glu100/Asp122 in MC4R) located at the extracellular tops of TM2 and TM3, contributing to orthosteric binding.

Free L-histidine exists in two tautomeric forms — Nτ-H (tau, the 'productive' donor form) and Nπ-H (pi) — in roughly equal equilibrium at physiological pH. Only the Nτ-H tautomer is geometrically positioned to donate the hydrogen bond required for the MC4R acidic-cluster interaction. Native Semax therefore uses only ~50% of its His-3 population in the binding-competent configuration at any given moment, representing an affinity ceiling imposed by tautomeric entropy.

The proposed modification — methylation of the π-nitrogen (N1/Nπ) to produce 1-methyl-L-histidine — eliminates the Nπ-H tautomer entirely. The imidazole is locked in the τ-tautomer (Nτ-H permanently exposed), presenting the H-bond donor continuously and removing the entropic cost of tautomeric interconversion. Secondarily, the N-methyl group adds a hydrophobic surface for potential contact with the TM3 aromatic shelf residue Phe261, without altering the ring's planar geometry or the position of Nτ-H.

Performance Applications

If validated experimentally, enhanced MC4R affinity of ME-(1Me-His)-FPGP could translate to several performance-relevant domains where MC4R signaling plays a role:

• Cognitive function and attention: MC4R is expressed in the hypothalamus, hippocampus, and cortex, with established roles in synaptic plasticity, attention, and learning consolidation. Tighter MC4R engagement could amplify Semax's documented nootropic effects — which are currently attributed primarily to BDNF/TrkB upregulation and monoaminergic modulation — through an additional melanocortinergic mechanism.
• Energy balance and metabolic signaling: MC4R is a central regulator of energy homeostasis; improved agonist potency at this receptor has metabolic implications, including satiety signaling. This would be a secondary consideration for a cognitive-use peptide but is physiologically relevant.
• Neuroprotection: MC4R agonism has been linked to anti-inflammatory neuroprotection in rodent models, a pathway complementary to Semax's known neuroprotective activity through neurotrophic mechanisms.

Important caveat: Semax's MC4R activity has not been directly measured in the published literature. The performance implications above are conditional on the receptor assignment being correct, which remains unvalidated experimentally.

Modification Rationale

The tautomer-locking strategy via Nπ-methylation is a recognized tactic in GPCR medicinal chemistry, particularly in melanocortin SAR work, where the τ-tautomer preference at the receptor binding site has been characterized. By methylating N1 rather than N3 (Nτ), the modification:

1. Forces the productive tautomer — Nτ-H is the sole available form, doubling the effective binding-competent population relative to native His.
2. Adds steric complementarity — the methyl group projects toward the TM3 aromatic shelf without clashing with the acidic cluster contact geometry.
3. Preserves backbone conformation — 1-methyl-L-histidine maintains the same α-carbon geometry as L-His; no backbone perturbation is expected, consistent with the prediction (RMSD estimated < 0.8 Å).
4. Is chemically stable — the N-methyl group is metabolically inert to ring oxidation; this may modestly improve metabolic stability relative to native His, which is susceptible to imidazole oxidation.

This modification is strategically distinct from the two prior Semax folds in this lab:

• Fold №1 (N-terminal acetylation, REFINED) targeted Met-1 for half-life extension via aminopeptidase protection — a metabolic stability mechanism, not affinity.
• Fold №24 (4F-Phe at position 4, DISCARDED) targeted the phenylalanine aromatic pocket via electronic modulation — a different residue, different mechanism, and yielded a poor interface confidence. The current fold's ipTM of 0.89 substantially outperforms the interface confidence that caused Fold №24's discard, lending credibility to the His-3 locus as more pharmacophore-critical than Phe-4 for MC4R engagement.

Predicted Properties (Favourable Changes from Native Semax)

The most significant predicted gains are at the receptor interface level — the ipTM of 0.89 is among the strongest interface confidence values produced in this lab's Semax series, suggesting that the predicted complex geometry is robust. The trade-off is the likely loss of Cu(II)-chelating pharmacology, a confirmed mechanism for native Semax.

Suggested Next Steps

Further computational variants:

• Fold №50 candidate — 3-methyl-L-histidine (Nτ-methyl): As a direct negative control, methylating the productive nitrogen (Nτ) should abolish MC4R binding if the τ-tautomer contact hypothesis is correct. A low ipTM prediction for this variant would strongly validate the tautomer-locking mechanism computationally.
• Dual modification — Fold №1 × Fold №49: Combine N-terminal acetylation (Fold №1, REFINED) with His-3 → 1Me-His to stack the half-life extension mechanism with the predicted affinity gain. Predict: Ac-ME-(1Me-His)-FPGP.
• Chai-1 ensemble run: Re-run ME-(1Me-His)-FPGP against MC4R with Chai-1 to generate a second-model agreement score and increase prediction confidence. The absence of Chai-1 agreement in this fold is the primary remaining uncertainty.

Validation experiments (wet lab):

• RadioligandBinding assay (MC4R): Competitive displacement of [¹²⁵I]-NDP-α-MSH in MC4R-expressing HEK293 cells to establish Ki for both native Semax and ME-(1Me-His)-FPGP. This is the essential first experiment — no baseline Semax-MC4R Ki is published.
• cAMP functional assay: MC4R is Gs-coupled; cAMP accumulation in MC4R-transfected cells provides EC50/Emax for agonist potency and efficacy — distinct from binding affinity alone.
• Cu(II) chelation titration (UV-vis / ITC): Confirm that Nπ-methylation abolishes or attenuates Cu(II) coordination as predicted, to characterize the pharmacological trade-off explicitly before in vivo work.
• Plasma stability (HPLC): Half-life of ME-(1Me-His)-FPGP vs. native Semax in human plasma, to quantify the metabolic stability contribution of the 1-methyl-imidazole.
• Selectivity panel (MC1R, MC3R): Given the absence of selectivity data for Semax at melanocortin receptor subtypes, profiling ME-(1Me-His)-FPGP across the MCR family would establish whether tautomer locking improves MC4R selectivity or broadly increases MCR affinity.